Expanding Immunotherapy Options for Liver Cancer Patients

As a result of the new approval, pembrolizumab can now be used for treating patients with hepatocellular carcinoma — the most common form of primary liver ...

Immunotherapy for Liver Cancer - Cancer Research Institute

Immunotherapy for liver cancer can enhance cancer-fighting immune system responses, but may not always be available or viable for patients with a history of ...

Expanding the immunotherapy roadmap for hepatocellular carcinoma

In Lancet Oncology, Yau et al., (2022) recently reported on the CheckMate 459 trial, an open-label, phase III trial that randomized patients to nivolumab versus ...

FDA Approves New Immunotherapy Combination To Treat ...

“While there is a heartbreaking need for more effective liver cancer treatments, this new immunotherapy combination can help more patients live ...

Immunotherapy for hepatocellular carcinoma: Current status and ...

In current years, cancer immunotherapy has made significant progress, opening up new treatment options for HCC. ... patients with unresectable primary liver ...

A New Strategy to Transform Liver Cancer Immunotherapy

For most liver cancer patients, immunotherapy does not produce effective results but new data suggests a revamped strategy can make unresponsive ...

The next evolution in expanding access to liver transplantation

In pre-transplant patients, immunotherapy may improve downstaging success and tumour control at the cost of some immunologic risks. These include immune-related ...

6 Innovative Liver Cancer Treatment Options

Immunotherapy recruits the patient's own immune system in the fight against cancer. This can be used on its own or in combination with other therapies. Targeted ...

Expanding the Use of an Immunotherapeutic to Liver Cancer

... patients with hepatocellular carcinoma – the most common form of primary liver cancer ... Expanding Immunotherapy Options for Liver... Adjuvant Treatment With ...

Transplantation for Advanced Liver Cancer Patients - Cedars-Sinai

Now a study led by Cedars-Sinai Cancer investigators has concluded that immunotherapy could make liver transplant an option for patients ...

Biomarker May Predict Immunotherapy Response in Liver Cancer

Until recently, patients with hepatocellular carcinoma had few treatment options, and those that were available extended life by only a few ...

Expanding Immunotherapy Armamentarium Propels Personalized ...

Richard Kim, MD, discusses the range of systemic treatment options available for patients with unresectable hepatocellular carcinoma and the ...

Immunotherapy for liver cancer

Immunotherapy helps to strengthen or restore the immune system's ability to fight cancer. This works to kill cancer cells and stop cancer cells from growing ...

Immunotherapy and targeted drugs for liver cancer

Immunotherapy uses our immune system to fight cancer. It works by helping the immune system recognise and attack cancer cells. Targeted drugs ...

FDA Approves Atezolizumab Plus Bevacizumab for Liver Cancer - NCI

FDA has approved the immunotherapy drug atezolizumab, used with bevacizumab, to treat some patients with advanced liver cancer.

Advances in immunotherapy for hepatocellular carcinoma - Nature

Due to a strong and broad resistance of HCC to cytotoxic chemotherapy, systemic therapy was for many years a deferred option in HCC. In 2008, ...

New treatment extends lives of people with most common type of ...

Researchers found that a combination of atezolizumab, an immunotherapy drug that boosts the body's natural defenses, and bevacizumab, an anti- ...

The next evolution in expanding access to liver transplantation

Immunotherapy has revolutionised cancer treatment, including the treatment of hepatocellular carcinoma (HCC), the third leading cause of cancer death in the ...

Personalized Vaccine for Liver Cancer Shows Promise in Clinical Trial

All patients received the PD-1 inhibitor pembrolizumab in combination with a personalized anti-tumor vaccine. The most common adverse effect ...

Nivolumab Approved by FDA for Liver Cancer - NCI

The immunotherapy nivolumab (Opdivo®) has been approved by FDA for patients with advanced liver cancer who have previously been treated with ...